| Leishmaniasis & vaccine solutions |
| Lipopolysaccharides in vaccine adjuvants |
| Malaria vaccines |
| Malignant diseases & immune response |
| Medicinal chemistry in vaccine design |
| Monoclonal antibodies in immunotherapy |
| Mucosal vaccination & delivery systems |
| Nanovaccines & nanotechnology applications |
| Neglected tropical diseases |
| Nidoviruses |
| Onchocerciasis |
| Parasitic diseases & vaccine development |
| Pathogenesis & immune responses |
| Pathogenic Escherichia coli |
| Peptide-based vaccines |
| Pneumococcal conjugate vaccines |
| Polysaccharides in vaccines |
| Protozoal infections |
| Reverse vaccinology & computational immunology |
| RNA viruses & vaccine platforms |
| Schistosomiasis |
| Sepsis & immune modulation |
| SHIV & SIV vaccine models |
| Streptococcus equi & bacterial immunity |
| Swine fever vaccines |
| T-cell vaccines & immunotherapy |
| Tumor biology & immune response |
| Typhoid & enteric vaccines |
| Vaccine delivery & novel formulations |
| Vaccine development & regulatory frameworks |
| Vaccine-induced immunity & immune modulation |
| Viral diseases & pathogenesis |
| Viral immunology & host responses |
| Viral vaccine research & new platforms |
| Virology & viral replication mechanisms |
| Virulence factors & pathogen adaptation |
| Virus-host interactions & immune modulation |
| Zika virus & vaccine strategies |
| Zoonotic viral infections & pandemic threats |
| Zoster vaccine & herpes zoster prevention |
